Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Axsome Therapeutics Pretax Margin % Related Terms
Axsome Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Axsome Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:AZSM vs MDGL, IONS, BMRN: Pretax Margin % Comparison
For the Biotechnology subindustry, Axsome Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Axsome Therapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Axsome Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axsome Therapeutics (MEX:AZSM) has a Pretax Margin % of -33.76% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Axsome Therapeutics and its competitors. According to the industry distribution chart, Axsome Therapeutics ranks #363 out of 941 companies in the Biotechnology industry, placing it in the top 38.6%.
Is Axsome Therapeutics' Pretax Margin % too high?
Axsome Therapeutics' current Pretax Margin % is -33.76%. Based on the distribution chart, Axsome Therapeutics ranks #363 out of 941 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Axsome Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Pretax Margin % compare to MDGL and IONS?
According to the Biotechnology industry distribution chart, Axsome Therapeutics ranks #363 out of 941 companies for Pretax Margin %. This puts Axsome Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current Pretax Margin % is -33.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Axsome Therapeutics (MEX:AZSM) has a current Pretax Margin % of -33.76%. The stock's GF Value™ is MXN1,494.25, compared to a current price of MXN1,519.00 — trading 1.7% above its estimated fair value. The current Pretax Margin % is -33.76%. Axsome Therapeutics' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Axsome Therapeutics (MEX:AZSM), the current Pretax Margin % is -33.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Axsome Therapeutics (MEX:AZSM) Overvalued in 2026?
Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued.
The current stock price of MXN1,519.00 is trading 1.7% above its estimated GF Value™ of MXN1,494.25.
Key valuation signals for MEX:AZSM:
Pretax Margin %: -33.76%
GF Value™: MXN1,494.25 vs. price of MXN1,519.00 (1.7% above fair value)
No single metric tells the full story. See the MEX:AZSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score
Get the complete analysis for MEX:AZSM
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AZSM has been successfully added to your 
